A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1 (c2591) T Cells in HLA-A2+ Patients With Synovial Sarcoma

Condition(s)
Sarcoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Biological treatment cell Biological
NY-ESO-1 (c259) T Cells
Trial Summary & Details
Ages: 4 Years and older
Condition: Synovial Sarcoma

The purpose of this early (pilot) clinical trial is to test the effects (both good and bad) of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable, metastatic or recurrent synovial sarcoma.

Status
Active not recruiting
Location(s)
City of Hope, Duarte, CA
University of Miami, Sylvester Cancer Center, Miami, FL
Moffitt Cancer Center, Tampa, FL
National Cancer Institute, Bethesda, MD
Dana-Farber Cancer Institute, Boston, MA
Washington University School of Medicine, Saint Louis, MO
Memorial Sloan Kettering Cancer Center, New York, NY
Children's Hospital of Philadelphia, Philadelphia, PA
The University of Texas MD Anderson Cancer Center, Houston, TX
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Centre Léon Bérard & Université Claude Bernard, Lyon, France
Institut Gustave Roussy, Paris, France
University College London Hospital, London, United Kingdom
The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

Sponsor/Collaborator:
GlaxoSmithKline
Contact
US GSK Clinical Trials Call Center
877-379-3718